(LIVN) LivaNova - Overview
Stock: Heart-Lung Machine, Oxygenator, VNS System, Implantable Pulse Generator
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 38.8% |
| Relative Tail Risk | -18.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.80 |
| Alpha | 20.82 |
| Character TTM | |
|---|---|
| Beta | 0.932 |
| Beta Downside | 0.894 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.23% |
| CAGR/Max DD | 0.12 |
Description: LIVN LivaNova January 14, 2026
LivaNova PLC (NASDAQ:LIVN) is a London-based medical-technology firm that commercialises devices for both cardiac surgery and neurostimulation. Its two business lines are Cardiopulmonary – supplying heart-lung machines, oxygenators, autotransfusion and perfusion accessories – and Neuromodulation – offering the VNS Therapy System for drug-resistant epilepsy, treatment-resistant depression, and other vagus-nerve applications.
In FY 2023 the company reported approximately $1.5 billion in revenue, a 7 % YoY increase driven largely by higher demand for its perfusion products in emerging-market hospitals. R&D spending was about $150 million (≈10 % of sales), and cash on hand stood at $400 million, providing a runway for upcoming product launches and potential acquisitions.
Key macro drivers include the aging global population, which expands the pool of patients needing cardiac bypass and neurostimulation therapies, and the ongoing shift toward minimally invasive procedures that favor implantable devices. Reimbursement trends in the U.S. and EU are also critical; recent CMS updates have broadened coverage for VNS therapy, potentially accelerating adoption rates.
For a deeper, data-rich analysis of LIVN’s valuation metrics and scenario modeling, you may find ValueRay’s platform worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -217.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.18 > 1.0 |
| NWC/Revenue: 19.98% < 20% (prev 61.91%; Δ -41.92% < -1%) |
| CFO/TA 0.10 > 3% & CFO 250.7m > Net Income -217.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.2m) vs 12m ago 1.13% < -2% |
| Gross Margin: 68.50% > 18% (prev 0.67%; Δ 6782 % > 0.5%) |
| Asset Turnover: 53.12% > 50% (prev 49.24%; Δ 3.88% > 0%) |
| Interest Coverage Ratio: -2.54 > 6 (EBITDA TTM -83.2m / Interest Expense TTM 54.2m) |
Altman Z'' -1.99
| A: 0.11 (Total Current Assets 1.10b - Total Current Liabilities 827.6m) / Total Assets 2.56b |
| B: -0.46 (Retained Earnings -1.18b / Total Assets 2.56b) |
| C: -0.05 (EBIT TTM -137.8m / Avg Total Assets 2.54b) |
| D: -0.78 (Book Value of Equity -1.09b / Total Liabilities 1.40b) |
| Altman-Z'' Score: -1.99 = D |
Beneish M -3.09
| DSRI: 1.12 (Receivables 239.1m/197.2m, Revenue 1.35b/1.24b) |
| GMI: 0.98 (GM 68.50% / 67.46%) |
| AQI: 0.97 (AQ_t 0.47 / AQ_t-1 0.48) |
| SGI: 1.09 (Revenue 1.35b / 1.24b) |
| TATA: -0.18 (NI -217.5m - CFO 250.7m) / TA 2.56b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of LIVN shares?
Over the past week, the price has changed by +2.38%, over one month by +3.48%, over three months by +21.30% and over the past year by +35.61%.
Is LIVN a buy, sell or hold?
- StrongBuy: 4
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LIVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 73 | 11.6% |
| Analysts Target Price | 73 | 11.6% |
| ValueRay Target Price | 73.3 | 12.1% |
LIVN Fundamental Data Overview February 02, 2026
P/S = 2.6599
P/B = 3.1006
P/EG = 0.6681
Revenue TTM = 1.35b USD
EBIT TTM = -137.8m USD
EBITDA TTM = -83.2m USD
Long Term Debt = 349.0m USD (from longTermDebt, last quarter)
Short Term Debt = 94.4m USD (from shortTermDebt, last quarter)
Debt = 486.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -159.5m USD (from netDebt column, last quarter)
Enterprise Value = 3.43b USD (3.59b + Debt 486.5m - CCE 646.1m)
Interest Coverage Ratio = -2.54 (Ebit TTM -137.8m / Interest Expense TTM 54.2m)
EV/FCF = 17.91x (Enterprise Value 3.43b / FCF TTM 191.4m)
FCF Yield = 5.58% (FCF TTM 191.4m / Enterprise Value 3.43b)
FCF Margin = 14.19% (FCF TTM 191.4m / Revenue TTM 1.35b)
Net Margin = -16.12% (Net Income TTM -217.5m / Revenue TTM 1.35b)
Gross Margin = 68.50% ((Revenue TTM 1.35b - Cost of Revenue TTM 425.0m) / Revenue TTM)
Gross Margin QoQ = 68.45% (prev 67.79%)
Tobins Q-Ratio = 1.34 (Enterprise Value 3.43b / Total Assets 2.56b)
Interest Expense / Debt = 2.23% (Interest Expense 10.9m / Debt 486.5m)
Taxrate = 20.99% (7.11m / 33.9m)
NOPAT = -108.8m (EBIT -137.8m * (1 - 20.99%)) [loss with tax shield]
Current Ratio = 1.33 (Total Current Assets 1.10b / Total Current Liabilities 827.6m)
Debt / Equity = 0.42 (Debt 486.5m / totalStockholderEquity, last quarter 1.16b)
Debt / EBITDA = 1.92 (negative EBITDA) (Net Debt -159.5m / EBITDA -83.2m)
Debt / FCF = -0.83 (Net Debt -159.5m / FCF TTM 191.4m)
Total Stockholder Equity = 1.16b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.56% (Net Income -217.5m / Total Assets 2.56b)
RoE = -18.77% (Net Income TTM -217.5m / Total Stockholder Equity 1.16b)
RoCE = -9.14% (EBIT -137.8m / Capital Employed (Equity 1.16b + L.T.Debt 349.0m))
RoIC = -6.44% (negative operating profit) (NOPAT -108.8m / Invested Capital 1.69b)
WACC = 8.44% (E(3.59b)/V(4.07b) * Re(9.35%) + D(486.5m)/V(4.07b) * Rd(2.23%) * (1-Tc(0.21)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.83%
[DCF Debug] Terminal Value 79.83% ; FCFF base≈158.3m ; Y1≈195.3m ; Y5≈332.6m
Fair Price DCF = 97.35 (EV 5.16b - Net Debt -159.5m = Equity 5.32b / Shares 54.6m; r=8.44% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 19.28 | EPS CAGR: -40.57% | SUE: -4.0 | # QB: 0
Revenue Correlation: 93.79 | Revenue CAGR: 7.79% | SUE: 3.33 | # QB: 12
EPS next Quarter (2026-03-31): EPS=0.90 | Chg30d=+0.007 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=4.13 | Chg30d=-0.004 | Revisions Net=-2 | Growth EPS=+6.9% | Growth Revenue=+6.5%